Blood Flow Restriction Training in Women With Posterior Tibial Tendon Dysfunction
NCT: NCT07750106 · NOT_YET_RECRUITING
Brief Summary
Posterior tibial tendon dysfunction (PTTD) is a common musculoskeletal disorder characterized by pain, impaired foot function, and reduced dynamic stability. As one of the primary causes of adult-acquired flatfoot deformity, it can significantly affect walking ability, balance, and overall performance of daily activities. Although conventional rehabilitation typically emphasizes strengthening the posterior tibial tendon and surrounding muscles, these interventions may not fully address deficits in neuromuscular control and postural stability, highlighting the need for additional therapeutic approaches. This randomized controlled trial aims to evaluate whether incorporating blood flow restriction (BFR) training into a rehabilitation program provides additional benefits for postmenopausal women with Stage I or flexible Stage II PTTD. A total of 54 eligible participants will be randomly allocated to either a BFR training group or a conventional exercise group. Clinical outcomes will be assessed before and after the intervention, including dynamic postural stability measured with the Biodex Balance System and active and passive ankle joint position sense assessed using the Biodex Isokinetic Dynamometer.
Frequently Asked Questions
What is Blood Flow Restriction Training in Women With Posterior Tibial Tendon Dysfunction?
Blood Flow Restriction Training in Women With Posterior Tibial Tendon Dysfunction is a clinical trial registered under NCT07750106. Current status: NOT_YET_RECRUITING.
What is the status of NCT07750106?
The current status of NCT07750106 (Blood Flow Restriction Training in Women With Posterior Tibial Tendon Dysfunction) is: NOT_YET_RECRUITING.
When did Blood Flow Restriction Training in Women With Posterior Tibial Tendon Dysfunction start?
Blood Flow Restriction Training in Women With Posterior Tibial Tendon Dysfunction started on 2026-08-01.
Related Devices
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.